Cash and investments totaled $31.5 million as of September 30, 2022, as compared to $38.6 million as of June 30, 2022. "Miromatrix is excited to announce that we recently submitted our IND for miroliverELAP(TM)," said Jeff Ross, Ph.D., Miromatrix CEO. "We believe this is the first IND to be submitted to the FDA for a bioengineered organ. I am incredibly proud of our entire team for achieving this important milestone and putting us one step closer to our goal of treating patients with our bioengineered organs and eliminating the organ transplant waiting list."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MIRO:
- Miromatrix CEO Jeff Ross Delivering Keynote Address at ARMI | BioFabUSA 2022 Fall Summit: Meeting in the Millyard
- Miromatrix Medical management to meet with Piper Sandler
- Miromatrix CEO Jeff Ross to Present at the 2022 Cell & Gene Meeting on the Mesa
- William Blair biotech analysts to hold analyst/industry webinar
- Miromatrix CEO Jeff Ross to Present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event